LivaNova (LIVN) Cash from Investing Activities (2015 - 2026)
LivaNova (LIVN) reported Cash from Investing Activities of -$14.6 million for Q1 2026, down 37.18% on a YoY basis from -$23.2 million in Q1 2025, and up 51.82% sequentially from -$30.3 million in Q4 2025.
LivaNova (LIVN) Cash from Investing Activities (2015 - 2026) Analysis & Trends
LivaNova (LIVN) has 12 years of Cash from Investing Activities data on file, last reported at -$14.6 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities fell 37.18% year-over-year to -$14.6 million; the trailing twelve-month figure through Mar 2026 stood at -$76.9 million (down 46.62% YoY), and the FY2025 full-year result was -$72.9 million, down 51.4% from the prior year.
- Cash from Investing Activities grew to -$14.6 million in Q1 2026, from -$30.3 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of -$5.5 million in Q1 2022 to a low of -$30.3 million in Q4 2025.
- A 5-year average of -$12.6 million and a median of -$11.0 million in 2022 frame the typical range for Cash from Investing Activities.
- Across the five-year window, Cash from Investing Activities plunged 201.65% in 2022 and jumped 58.79% in 2023, its largest moves.
- Tracing LIVN's Cash from Investing Activities over 5 years: stood at -$11.0 million in 2022, then fell by 10.82% to -$12.1 million in 2023, then increased by 11.78% to -$10.7 million in 2024, then tumbled by 182.58% to -$30.3 million in 2025, then soared by 51.82% to -$14.6 million in 2026.
- Business Quant data shows LIVN's Cash from Investing Activities at -$14.6 million in Q1 2026, -$30.3 million in Q4 2025, and -$23.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | -20.32 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | -185.00 Mn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | -917.00 Mn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | -591.00 Mn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | -92.80 Mn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | -298.50 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -2.50 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | -475.32 Mn |
| 10 | LivaNova | 4.40 Bn | 3.86 Bn | 243.75 Mn | -14.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.58 Mn |
| Mar 31, 2026 | -14.58 Mn |
| Dec 31, 2025 | -30.26 Mn |
| Dec 31, 2025 | -30.26 Mn |
| Sep 30, 2025 | -23.06 Mn |
| Sep 30, 2025 | -23.06 Mn |
| Jun 30, 2025 | -8.97 Mn |
| Jun 30, 2025 | -8.97 Mn |
| Mar 31, 2025 | -10.63 Mn |
| Mar 31, 2025 | -10.63 Mn |
| Dec 31, 2024 | -10.71 Mn |
| Dec 31, 2024 | -10.71 Mn |
| Sep 30, 2024 | -18.52 Mn |
| Sep 30, 2024 | -18.52 Mn |
| Jun 30, 2024 | -12.57 Mn |
| Jun 30, 2024 | -12.57 Mn |
| Mar 31, 2024 | -6.36 Mn |
| Mar 31, 2024 | -6.36 Mn |
| Dec 31, 2023 | -12.14 Mn |
| Dec 31, 2023 | -12.14 Mn |